0001012975-20-000601.txt : 20200701 0001012975-20-000601.hdr.sgml : 20200701 20200701161436 ACCESSION NUMBER: 0001012975-20-000601 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200701 DATE AS OF CHANGE: 20200701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pivotal bioVenture Partners Fund I, L.P. CENTRAL INDEX KEY: 0001695076 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39343 FILM NUMBER: 201005506 BUSINESS ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (345) 949 1040 MAIL ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 FORMER NAME: FORMER CONFORMED NAME: Pivotal Venture Partners Fund I, L.P. DATE OF NAME CHANGE: 20170118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pivotal bioVenture Partners Fund I G.P., L.P. CENTRAL INDEX KEY: 0001752862 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39343 FILM NUMBER: 201005507 BUSINESS ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (415) 697-1002 MAIL ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akouos, Inc. CENTRAL INDEX KEY: 0001722271 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 645 SUMMER STREET, SUITE 200 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-245-5715 MAIL ADDRESS: STREET 1: 645 SUMMER STREET, SUITE 200 CITY: BOSTON STATE: MA ZIP: 02210 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2020-06-30 1 0001722271 Akouos, Inc. AKUS 0001695076 Pivotal bioVenture Partners Fund I, L.P. 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 0 0 1 0 0001752862 Pivotal bioVenture Partners Fund I G.P., L.P. 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 0 0 1 0 Common Stock 2020-06-30 4 C 0 1499971 A 1499971 I See footnote Common Stock 2020-06-30 4 P 0 294117 17.00 A 1794088 I See footnote Series B Preferred Stock 2020-06-30 4 C 0 1499971 0 D Common Stock 1499971 0 I See footnote On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., or Pivotal GP. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal. /s/ Heather Preston, MD - for Pivotal bioVenture Partners Fund I, L.P., as Managing Partner 2020-07-01 /s/ Heather Preston, MD - for Pivotal bioVenture Partners Fund I G.P., L.P., as Managing Partner 2020-07-01